Zobrazeno 1 - 10
of 16
pro vyhledávání: '"B. S. Glisson"'
Autor:
J E, Tseng, B S, Glisson, F R, Khuri, D M, Shin, J N, Myers, A K, El-Naggar, J S, Roach, L E, Ginsberg, P F, Thall, X, Wang, S, Teddy, K N, Lawhorn, R E, Zentgraf, G D, Steinhaus, J M, Pluda, J L, Abbruzzese, W K, Hong, R S, Herbst
Publikováno v:
Cancer. 92(9)
Thalidomide has been shown to have antiangiogenic effects in preclinical models as well as a significant antitumor effect in hematologic tumors such as multiple myeloma. The authors performed this Phase II study to determine the activity, toxicity pr
Autor:
D M, Shin, N J, Donato, R, Perez-Soler, H J, Shin, J Y, Wu, P, Zhang, K, Lawhorn, F R, Khuri, B S, Glisson, J, Myers, G, Clayman, D, Pfister, J, Falcey, H, Waksal, J, Mendelsohn, W K, Hong
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(5)
C225, a human-mouse chimerized monoclonal antibody directed against the epidermal growth factor receptor (EGFr), has a synergistic effect with cisplatin in xenograft models. To determine the tumor EGFr saturation dose with C225 and the fate of infuse
Publikováno v:
Seminars in oncology. 27(4 Suppl 8)
Patients with advanced squamous cell head and neck cancer have a dismal long-term survival rate not only because of metastatic disease, but also primarily because of failure in local disease control. The role of chemotherapy in recurrent or metastati
Autor:
J A, Roth, S G, Swisher, J A, Merritt, D D, Lawrence, B L, Kemp, C H, Carrasco, A K, El-Naggar, F V, Fossella, B S, Glisson, W K, Hong, F R, Khurl, J M, Kurie, J C, Nesbitt, K, Pisters, J B, Putnam, D S, Schrump, D M, Shin, G L, Walsh
Publikováno v:
Seminars in oncology. 25(3 Suppl 8)
The identification of genetic lesions that lead a normal cell to become malignant presents us with the opportunity of targeting those lesions as a means of therapy. Given the key role played by the tumor suppressor gene p53 in cell cycle regulation a
Publikováno v:
Seminars in oncology. 25(2 Suppl 4)
This phase I/II study investigated the efficacy and toxic effects of combination chemotherapy using paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), ifosfamide, and cisplatin (TIP) in patients with recurrent or metastatic squamous cel
Publikováno v:
Seminars in oncology. 24(6 Suppl 19)
Current chemotherapeutic approaches to recurrent or metastatic head and neck cancer have yielded response rates of 10% to 20% for single agents and 30% to 40% for combination chemotherapy. Median survival for patients with recurrent or metastatic dis
Publikováno v:
Seminars in oncology. 24(4 Suppl 12)
Chemotherapy has been rarely considered an important treatment modality for brain metastases. Based on the hypothesis that the lack of efficacy of chemotherapy, rather than the blood-brain barrier itself, may be the major hindrance to the successful
Autor:
F B, Geara, B S, Glisson, G, Sanguineti, S L, Tucker, A S, Garden, K K, Ang, S M, Lippman, G L, Clayman, H, Goepfert, L J, Peters, W K, Hong
Publikováno v:
Cancer. 79(7)
Prospective randomized and retrospective studies on adjunctive chemotherapy in patients with advanced locoregional nasopharyngeal carcinoma have yielded conflicting results and the role of chemotherapy in this disease had not been clearly defined. Th
Publikováno v:
Lymphokine and cytokine research. 13(2)
Recent evidence suggests that deficient HLA Class I expression in SCLC lines may be due, in part, to down-regulation of TAP-1 and TAP-2 expression, and, thus, deficient antigen processing. Given the capability of the multidrug transporter mediating M
Autor:
A. L. Sabichi, M. S. Kies, B. S. Glisson, C. Lu, L. E. Ginsberg, C. I. Bartos, L. Feng, H. T. Tran, S. M. Lippman, G. R. Blumenschein
Publikováno v:
Journal of Clinical Oncology. 28:5532-5532